AUS
NZ
UK
CA
USA
IND
Highlights
- PYC Therapeutics presents trial data for VP-001 at a major conference.
- Phase 1/2 studies focus on treating Retinitis Pigmentosa Type 11.
- Preparations for FDA discussions regarding a registrational trial are underway.
PYC Therapeutics (ASX:PYC), a clinical-stage biotech company, is advancing its drug development efforts to tackle childhood blindness caused by Retinitis Pigmentosa Type 11 (RP11). ASX healthcare stock Opthea Limited highlighted its flagship drug candidate, VP-001, as the first potential treatment for a rare blinding eye disease. Updates from its Phase 1/2 trial were presented at the Asia Pacific Vitreo-Retina Society (APVRS) conference in Singapore on November 23.
The presentation, led by Associate Professor Fred Chen of the Lion’s Eye Institute, highlighted promising developments in VP-001’s clinical journey. Prof. Chen, a consultant ophthalmologist at Royal Perth Hospital and Perth Children’s Hospital, delved into the significant progress observed in the trial. His findings noted improved vision in eyes treated with VP-001 compared to untreated eyes and baseline readings, offering hope for addressing this critical medical condition.
This presentation marks an important step for PYC Therapeutics as it gears up for crucial discussions with the US Food and Drug Administration (FDA) about a registrational trial for VP-001. Scheduled to begin mid-2025, this trial will focus on demonstrating VP-001’s efficacy and safety in treating RP11. In the first half of 2025, the company will concentrate its efforts on collaborating with the FDA to finalize the trial’s design.
The conference serves as a global platform to highlight the advancements made by PYC Therapeutics in addressing RP11. It also emphasizes the potential impact of VP-001 in transforming patient outcomes in rare eye disorders.
Market activity surrounding PYC Therapeutics reflected growing interest in the company’s developments. On the day of the announcement, shares rose by 0.55%, trading at $1.83 at 13:08 AEDT.
PYC Therapeutics continues to drive forward its mission to develop innovative treatments for rare diseases. The company’s upcoming engagements with the FDA and the progress shared at the APVRS conference underscore its commitment to advancing therapies for unmet medical needs in ophthalmology.
